Additionally, genetic ablation of NOS2 in a genetically engineered mouse model of pancreatic cancer significantly increases survival, thus, providing proof-of-concept that therapies targeting NOS2 may improve survival in patients with PDAC. This evidence concerns the gene NOS2 and familial pancreatic carcinoma.